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Introduction: Recombinant human endostatin is a novel inhibitor of
tumor angiogenesis that acts specifically on neovascular endothelial
cells. Studies have shown that endostar plus vinorelbine-cisplatin
chemotherapy could improve objective response rates (ORR) and
overall survival (OS) of advanced non-small cell lung cancer
(NSCLC) patients. This study is to explore the clinical efficacy of
endostar plus paclitaxel-carboplatin (TC) in advanced NSCLC
patients.
Methods: A phase II, multicenter, randomized, double-blind, pla-
cebo-controlled study was carried out. Patients were randomly
assigned to the treatment (TC  endostar) or the control group (TC
 placebo). The efficacy was evaluated at the end of each cycle.
Follow-up continued until disease progression or death.
Results: A total of 126 patients were enrolled, of whom 122 were
evaluable, with 61 in each group. ORR was 39.3% in the treatment
group versus 23.0% in the control group (p 0.078), and the disease
control rate was 90.2% versus 67.2% (p  0.004), respectively. The
median progression-free survival (PFS) was 7.1 versus 6.3 months
(p  0.522) in the treatment and control groups, the 24-week rate of
PFS was 78% versus 59% (p 0.017), and the median OS was 17.6
versus 15.8 months (p  0.696), respectively. There were no
significant differences, either in the incidence of adverse events or
serious adverse events, between the two groups.
Conclusions: In previously untreated, advanced NSCLC patients,
treatment with TC plus endostar seemed to improve ORR. However,
the differences in PFS or OS between the two groups were not
statistically significant. Treatment with TC plus endostar exhibited a
good safety profile.
Key Words: Recombinant human endostatin, Endostar, Paclitaxel,
Carboplatin, NSCLC.
(J Thorac Oncol. 2011;6: 1104–1109)
Lung cancer is one of the most malignant tumors, repre-senting a significant threat to human health. In China,
about 500,000 new patients are diagnosed each year, with the
number expected to be 1 million in 2025.1 The majority of
non-small cell lung cancer (NSCLC) patients are at unresect-
able stage IIIB or IV disease when diagnosed. For these
patients, chemotherapy is the primary therapeutic option.
However, the response rate of chemotherapy for advanced
NSCLC is only 30% and has reached a plateau.2 Thus, there
is an urgent need to find a new strategy for NSCLC therapy.
In recent years, the clinical application of antiangio-
genic therapy has brought promise for the treatment of
NSCLC and has become an important addition in the treat-
ment of tumor invasion and metastasis. It has been proposed
that tumor growth is dependent on neoangiogenesis, and this
has been confirmed by basic and clinical research.3 In 1997,
a peptide was isolated from mouse hemangioendothelioma,
with a molecular weight of about 20 kD.4 By amino acid
sequencing, this peptide was confirmed to be a C-terminal
fragment of type XVIII collagen; it had antiangiogenic effects
and was named endostatin. The same researchers then treated
mice bearing Lewis lung cancer with murine endostatin and
found that the size of primary tumors was decreased to less
than 1 mm3 and that the tumor cells entered quiescence.5
The direct target of endostatin was new capillary en-
dothelial cells around the tumor. Furthermore and impor-
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tantly, it did not exhibit toxic effects in normal cells. More
recent preclinical studies have indicated that endostatin is one
of the most effective angiogenesis inhibitors currently
known.6,7 Endostatin specifically acts on neovascular endo-
thelial cells, inhibits cell migration, and induce cell apoptosis,
thus playing a major antiangiogenic role by acting on tumor-
associated neovascular endothelial cells. In addition, endosta-
tin seems to play a multitarget antiangiogenic role by regu-
lating expression of vascular endothelial growth factor and
activity of proteolytic enzymes, indirectly leading to the
quiescence or reduction of tumors. Recombinant human en-
dostatin (rh-endostatin) has been produced by the Entremed
Company using a yeast expression system. Phase I and II
clinical trials were conducted in September 1999 and October
2002, respectively.8
In 2005, China State Food and Drug Administration
licensed endostar plus vinorelbine-cisplatin (NP) to treat
advanced NSCLC as a first-line therapy. The decision was
mainly based on a phase III study,9 which was a randomized,
double-blind, multicenter trial comparing treatment with NP
plus endostar and NP alone, first line, in advanced NSCLC
patients. The objective response rates (ORR) in the NP plus
endostar group (N  322) and the NP alone group (N  164)
were 35.4% and 19.5% (p  0.01), the median time to
progression 6.3 and 3.6 months (p  0.001), the median
survival time 14.8 and 9.9 months (p 0.001), and the 1-year
survival rate 62.7% and 31.5% (p 0.001), respectively. The
incidence and severity of adverse events were comparable
between the two groups. These results indicated that en-
dostar exhibited synergistic effects with NP. Endostar not
only increased the response rate but also significantly
improved the overall survival (OS) without increasing the
adverse effects.
Paclitaxel-carboplatin (TC) is the first-line treatment
for NSCLC approved by the US Food and Drug Administra-
tion. We assumed that this TC chemotherapy plus endostar
could also improve the clinical efficacy in advanced NSCLC
patients. Therefore, we conducted an exploratory, random-
ized, double-blind, placebo-controlled, multicenter trial to
compare the clinical efficacy of endostar plus TC and TC




This study was an exploratory, randomized, double-
blind, placebo-controlled, multicenter phase II trial. The pri-
mary end point was progression-free survival (PFS); the
secondary end points included ORR, OS, and safety.
Patients eligible for this study needed to meet the
following inclusion criteria: histologically or cytologically
confirmed, previously untreated stage IIIB or IV NSCLC;
Eastern Cooperative Oncology Group performance status of 0
to 2; and measurable lung lesions (according to RECIST
criteria10). Exclusion criteria were as follows: symptomatic
brain metastases; bone metastases and related complications
or cognitive disabilities; bleeding diathesis or coagulopathy;
major organ dysfunction or other serious complications; preg-
nant or lactating women; and patients who participated in
other clinical trials within 4 weeks before the study.
After signing informed consent, patients received a
cycle of TC chemotherapy. The 126 patients who were
evaluated as having stable disease or better, and met the other
inclusion criteria, were randomly assigned to the treatment
group (TC  endostar) or the control group (TC  placebo).
Patients subsequently received another three cycles of treat-
ment in both groups. Efficacy was evaluated at the end of
each cycle, and had to be confirmed if it was a stable disease
(SD) or better. Follow-up continued after the end of treatment
and was conducted every 2 months until disease progression
or death. Safety was evaluated based on adverse events, vital
signs, or laboratory changes. Toxicity and adverse events
were classified according to Common Toxicity Criteria
(CTC, version 2) of the National Cancer Institute.
Blinding and Quality Control
This was a double-blind study. Random codes were
generated via a randomized method by an independent bio-
statistician. Based on these random codes, agents were num-
bered by the staff who was not involved in this trial. Patients
were enrolled in a competitive program, and agents were
distributed in sequence. Two-step unblinding was used.
During the trial, clinical monitors visited the hospitals
periodically to ensure that all regulations were being fol-
lowed. Data management was performed by the Department
of Epidemiology and Health Statistics, Nanjing Medical Uni-
versity. To ensure the accuracy of data entry, the data were
independently input twice and then proofread.
Informed Consent and Ethics
The clinical trial was strictly in compliance with the
ethical guidelines for human medical research in the Decla-
ration of Helsinki. The research program was in line with the
standards of Good Clinical Practice proposed by the State
Food and Drug Administration. The clinical trial was ap-
proved by the Medical Ethics Committees of the head unit,
Shanghai Chest Hospital, and all other participating units
(Ethics Approval No.: 2007-11 and 2007-24).
Before joining the trial, all patients were informed of
the details by the researchers and given sufficient time to
consider their options. They voluntarily agreed to participate
in the trial and signed the informed consent form.
Treatment Schemes
Endostar (injection of recombinant human endostatin)
was a product of Shandong Simcere-Medgenn Bio-Pharma-
ceuticals (National Medicine Permit No.: S20050088). Pla-
cebo was also produced by this company. Paclitaxel and
carboplatin were obtained from the Bristol-Myers Squibb
Company.
Paclitaxel (175 mg/m2) and carboplatin (AUC  5),
were administered (intravenously) on the first day of each
21-day cycle. Patients also received endostar (7.5 mg/m2/d)
or placebo on the 8 to 21 days of every cycle. Endostar was
dissolved in 250 ml normal saline and administered by
intravenous infusion for at least 3 hours.
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After the first course of PC alone, to determine eligi-
bility, patients in both groups received treatment for three
cycles, with one cycle being 21 days. If intolerable adverse
events, serious protocol violations, or disease progression
were observed, the treatment was terminated.
Statistical Analysis
Continuous variables were summarized by the mean,
SD, median, minimum, and maximum. Categorical variables
were summarized by frequencies and percentages. Efficacy
analysis was performed on the intent-to-treat (ITT) popula-
tion. The ORR and the disease control rate (DCR) were
calculated for each group, and the groups were compared
using Fisher’s exact test. Event-time distributions were esti-
mated by the Kaplan-Meier method. The Cox model with
time-dependent variables was used to estimate hazard ratios
for tumor progression at different study periods.11 Descriptive
analysis was used to summarize the safety data. Adverse
events were compared using Fisher’s exact test. All reported
p values were two sided, and values 0.05 was considered to
be statistically different. Confidence intervals (CIs) are at the
95% level.
RESULTS
Between July 18, 2007, and August 8, 2008, 126
patients with previously untreated, advanced NSCLC were
enrolled in this study and randomly assigned to the treatment
group (n  63) or the control group (n  63). One patient in
each group did not start treatment, and one patient in each
group was excluded for being allergic to paclitaxel. Accord-
ing to the ITT principle, there were 122 cases included in the
efficacy analysis, 61 in each group. Baseline characteristics of
patients in the two groups are summarized in Table 1. The
two groups were well balanced, except for a difference in
distribution according to sex (men accounted for 80.3% of
patients in the treatment group and 62.3% of those in the
control group; p  0.045, with Fisher’s exact test).
There were 124 cases in the safety analysis set, 62 cases
in each group. By September 14, 2010, one patient in the
treatment group and three patients in the control group were
lost to follow-up, giving a total lost to follow-up rate of 3.3%
(Figure 1).
Efficacy
In the ITT population, ORR in the treatment group was
moderately higher than that in the control group (39.3%
versus 23.0%, p  0.078). The DCR in the treatment group
was also significantly higher than that in the control group
(90.2% versus 67.2%, p  0.004). The median PFS was 7.1
months (95% CI: 6.6–7.7) in the treatment group and 6.3
months (95% CI: 5.6–6.9) in the control group, with no
significant difference (p  0.522, hazard ratio  0.883, 95%
CI: 0.604–1.292). The 24-week rates of PFS in the treatment
group and control group were 78% and 59%, respectively
(p  0.017). By September 14, 2010, a total of 90 deaths
(71%) were observed, 48 cases (76.2%) in the treatment
group and 42 cases (66.7%) in the control group. The 1-year
survival rates in the treatment group and the control group
were 61.7% and 55.1% (p  0.462), and the 2-year survival
rates were 31.4% and 36.1% (p  0.589), respectively. The
median OS in the treatment group and control group was 17.6
months (95% CI: 13.4–21.7) and 15.8 months (95% CI:
9.4–22.9) (p  0.696), respectively (Table 2 and Figure 2).
Safety
In the safety analysis set population, the incidence rate
of drug-related adverse events was 51.6% in the treatment











Male 49 (80.3) 38 (62.3)




Disease stage at entry, n (%)
IIIB 18 (29.5) 25 (41.0)
IV 43 (70.5) 36 (59.0)
Histology, n (%)
Squamous carcinoma 23 (37.7) 14 (23.0)
Adenocarcinoma 37 (60.7) 41 (67.2)
Other 1 (1.6) 6 (9.8)
ECOG performance status, n (%)
0 9 (14.8) 4 (6.6)
1 48 (78.7) 55 (90.2)
2 4 (6.6) 2 (3.3)
Smoking index, n (%)
400 34 (55.7) 42 (68.9)
400 27 (44.3) 19 (31.1)
ECOG, Eastern Cooperative Oncology Group.
FIGURE 1. Enrollment, randomization, and follow-up of
patients in the study.
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group and 50.0% in the control group. The incidence rate of
drug-related CTC grade 3 or 4 adverse events was 24.2% in
the treatment group and 35.5% in the control group. The
incidence rate of serious adverse events was 3.2% in the
treatment group and 8.1% in the control group. There were
no significant differences between the two groups. Com-
mon adverse events observed in the two groups are sum-
marized in Table 3.
The incidence rates of arrhythmia and myocardial isch-
emia were 8.1% and 4.8% in the treatment group and 4.8%
and 3.2% in the control group, respectively. Arrhythmia and
myocardial ischemia were grade 1 or 2, with no significant
difference between the two groups.
There was no significant difference between the two
groups in the change of vital signs before and after the
treatment. After treatment, mild electrocardiogram changes
were observed in seven cases in the treatment group and three
cases in the control group.
DISCUSSION
TC is a standard first-line treatment for NSCLC.12 Our
study addressed to the question of whether endostar in com-
bination with TC chemotherapy could benefit patients with
advanced NSCLC. The primary end point of PFS showed a
negative result (p  0.522), and the OS difference was not
statistically significant. However, endostar combined with TC
did improve ORR, DCR, and the 24-week rates of PFS. In
addition, treatment with TC plus endostar did not increase
toxicity, especially those typically observed in other antian-
FIGURE 2. Progression-free survival and overall
survival.
TABLE 3. Adverse Events
Adverse Events
Endostar  Paclitaxel/
Carboplatin (N  62)
Placebo  Paclitaxel/










Granulocytopenia 43 (69.4) 25 (40.3) 46 (74.2) 30 (48.4)
Hemoglobin reduction 49 (79.0) 0 (0.0) 54 (87.1) 2 (3.2)
Leukopenia 54 (87.1) 17 (27.4) 56 (90.3) 25 (40.3)
Lymphopenia 9 (14.5) 4 (6.5) 14 (22.6) 10 (16.1)
Thrombocytopenia 19 (30.6) 1 (1.6) 20 (32.3) 2 (3.2)
Nonhematological toxicity
Alopecia 35 (56.5) 39 (62.9)
Arrhythmia 5 (8.1) 0 (0.0) 3 (4.8) 0 (0.0)
Infection 3 (4.8) 0 (0.0) 5 (8.1) 2 (3.2)
Myocardial ischemia 3 (4.8) 0 (0.0) 2 (3.2) 0 (0.0)
Nausea 12 (19.4) 1 (1.6) 13 (21.0) 0 (0.0)
Sensory nervous system disorder 13 (21.0) 1 (1.6) 16 (25.8) 0 (0.0)
Skin disorder 5 (8.1) 0 (0.0) 4 (6.5) 0 (0.0)
Transaminase elevation 16 (25.8) 1 (1.6) 14 (22.6) 0 (0.0)
Vomiting 9 (14.5) 1 (1.6) 4 (6.5) 0 (0.0)
Values are given as number of patients (%).
CTC, Common Toxicity Criteria.
TABLE 2. The Efficacy of Paclitaxel-Carboplatin Alone or






(N  61) p
ORR 24 (39.3%) 14 (23.0%) 0.078
DCR 55 (90.2%) 41 (67.2%) 0.004
PFS (95% CI), mo 7.1 (6.6–7.7) 6.3 (5.6–6.9) 0.522
OS (95% CI), mo 17.6 (13.4–21.7) 15.8 (9.4–22.9) 0.696
TC, paclitaxel-carboplatin; ORR, objective response rate; DCR, disease control
rate; PFS, progression-free survival; OS, overall survival; CI, confidence interval.
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giogenesis therapies, such as hemorrhage and cardiovascular
toxicity. It also did not significantly increase the risk of
hemorrhage in patients with squamous carcinoma.
In the E4599 and AVAiL studies, the antiangiogenesis
agent, bevacizumab plus chemotherapy, not only increased
ORR but also improved PFS.13,14 However, in our phase II
study, PFS curves of the two groups approached each other in
the later part of the study. The reason might be that endostar
treatment was stopped after three cycles, whereas in the
E4599 study, patients in the TC plus bevacizumab group
continued to receive bevacizumab monotherapy every 3
weeks until evidence of disease progression or unacceptable
toxic effects developed. In the AVAiL study, 94% of eligible
patients received bevacizumab maintenance therapy, with a
median time of bevacizumab usage of six cycles. This observa-
tion may indicate the importance of maintaining endostar ther-
apy. The OS differences between our two groups were also not
significant, although the second-line treatment may have had
some effects on the result. When patients were allowed to take
other therapies, 15 patients (24.6%) in the treatment group
received other chemotherapies, with none receiving epidermal
growth factor receptor tyrosine kinase inhibitor treatment. In the
control group, 12 patients (19.7%) received other chemothera-
pies, with 6 (9.8%) receiving epidermal growth factor receptor
tyrosine kinase inhibitor treatment.
One cycle of TC chemotherapy was applied to screen
the patients in our study because lung cancer patients do not
seem to benefit from antiangiogenesis as monotherapy, such
as bevacizumab or endostar alone. The response rate of
endostar alone in advanced NSCLC patients was only 3%.15
Therefore, endostar seems to enhance the efficacy of chemo-
therapy. However, there is no evidence that it reverses the
chemotherapy resistance. From our previous experience, ef-
fective chemotherapy was a prerequisite for the efficacy of
this combination therapy. Effective chemotherapy may de-
crease tumor load, reduce tumor activity, and decrease the
secretion of angiogenic cytokines in tumors.16,17 Moreover,
antiangiogenesis therapy is believed to block tumor angio-
genesis and cut off the supply system of tumor growth, thus
increasing the efficacy of chemotherapy and perhaps extend-
ing the duration of its effectiveness. The combination of
chemotherapy and antiangiogenesis therapy has been proven
effective to treat cancers in recent years. However, there are
still many unsolved problems. For instance, which patients
are the most suitable for such combination therapy and which
biomarkers could predict efficacy? In this study, we tried to
use chemotherapy effectiveness as a screening criterion, with
only those patients evaluated as SD or better after one cycle
of chemotherapy alone, who were randomly assigned to the
treatment or the control group. The sample size was too small
to apply stratified randomization; hence, there was a differ-
ence in distribution according to sex between the two groups.
Nevertheless, the other baseline characteristics of the patients
were well balanced.
Special attention was given to those toxic effects typi-
cally observed in antiangiogenesis treatment. In the treatment
group, five patients (8.1%) were reported to have arrhythmia
and three patients (4.8%) developed myocardial ischemia. In
the control group, three patients (4.8%) had arrhythmia and
two patients (3.2%) myocardial ischemia. All were CTC
grade 1 or 2 and did not influence further treatment. Although
there were no significant differences between the two groups,
incidences of arrhythmia and myocardial ischemia were
slightly higher in the treatment group, something that should
be followed in future studies. This study did not exclude
patients with squamous cell carcinoma. Twenty-three patients
(37.7%) in the treatment group and 14 patients (23.0%) in the
control group had squamous histology. Of interest, no life-
threatening lung hemorrhage was observed, which was dif-
ferent from bevacizumab studies. The cause and mechanism
of this observation are unknown. One patient in the treatment
group had cerebral thrombosis after the first cycle of endostar
treatment and was withdrawn from study. In the control
group, two patients developed pulmonary embolism and one
had phlebothrombosis; all three cases were withdrawn from
study. Hypertension and proteinuria were not observed in the
treatment group. The incidence and severity of adverse events
were comparable between the two groups. Therefore, endo-
star, in combination with TC chemotherapy, was not shown
to increase toxicity.
In conclusion, endostar, in combination with TC che-
motherapy, was shown to slightly increase ORR but could not
significantly improve PFS and OS. Compared with other
antiangiogenesis treatment, endostar exhibited an excellent
safety profile. However, cardiac toxicity remains a concern.
Antiangiogenesis therapy is a promising method that has
become a part of the standard treatment for NSCLC.18 How-
ever, as a new strategy, it still has many issues to be resolved
by further studies.
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